Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03570619 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations(IMPACT) | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT01162135 | Digoxin for Recurrent Prostate Cancer | completed | Phase 2 | 16 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 |
| clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02025010 | Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03654638 | Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04600336 | Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer | completed | Phase 2 | 88 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03093428 | Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC | completed | Phase 2 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05137067 | A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents. | completed | Phase 2 | 90 | Optimal Health ResearchOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT04832958 | Imaging Guided Surgery to Improve the Detection of Lymph Node Metastases in Prostate Cancer Patients | completed | Phase 2 | 81 | IRCCS San RaffaeleOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT01309672 | S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy | completed | Phase 2 | 41 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 26, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT01254864 | Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | completed | Phase 2 | 190 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04869488 | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 93 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06398470 | Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal Microscopy | completed | Phase 1 / Phase 2 | 21 | University College, LondonOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04775602 | Experimental Study to Evaluate the Impact of 18 Fluoro-PSMA (18F-PSMA) PET / CT in the Management of Patients with Prostate Cancer.(F-PSMA) | completed | Phase 2 | 550 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT02643667 | Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer | completed | Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03454750 | Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)(LU-PSMA) | completed | Phase 2 | 143 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05146973 | External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) | completed | Phase 2 | 5 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT01784913 | A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer(UV1/hTERT2012P) | completed | Phase 1 / Phase 2 | 22 | Ultimovacs ASAINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03002220 | Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status(EXCAAPE) | completed | Phase 2 | 52 | MedSIROTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01650194 | A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients | completed | Phase 2 | 60 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02218606 | Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT02362464 | Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139 | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2024 | clinicaltrials |
| NCT01534052 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | completed | Phase 2 | 52 | Astellas Pharma IncINDUSTRY | 3 | Dec 6, 2024 | clinicaltrials |
| NCT02799745 | A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance(ENACT) | completed | Phase 2 | 227 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Dec 6, 2024 | clinicaltrials |
| NCT03707184 | Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone | completed | Phase 2 | 17 | University of UtahOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT01284920 | A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients | completed | Phase 1 / Phase 2 | 47 | Astellas Pharma IncINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT02124668 | A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 2 | 30 | Astellas Pharma Europe B.V.INDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT02787005 | Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199) | completed | Phase 2 | 388 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 21, 2024 | clinicaltrials |
| NCT03248570 | Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02213107 | Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. | completed | Phase 2 | 43 | University of RochesterOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03414034 | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05655715 | Checkpoint Inhibitors and SBRT for MCRPC(CheckPRO) | completed | Phase 2 | 90 | Herlev and Gentofte HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT03204812 | Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04060394 | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | completed | Phase 1 / Phase 2 | 49 | Laekna LimitedINDUSTRY | 2 | Oct 10, 2024 | clinicaltrials |
| NCT01774071 | Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT04207255 | Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | completed | Phase 2 | 69 | Medical University of South CarolinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT02099864 | Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | completed | Phase 2 | 36 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04733768 | 18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer | completed | Phase 2 | 100 | University of AlbertaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06601205 | Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.(2F) | completed | Phase 2 / Phase 3 | 125 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT00936936 | High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors | completed | Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | completed | Phase 1 / Phase 2 | 49 | Astex Pharmaceuticals, Inc.INDUSTRY | 4 | Aug 2, 2024 | clinicaltrials |
| NCT03336983 | Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients(BonEnza) | completed | Phase 2 | 126 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03339635 | Short-term Testosterone Replacement in Testicular Cancer Survivors | completed | Phase 2 | 32 | University Medical Center GroningenOTHER | 1 | Jul 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2025source: clinicaltrials